Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05035615 · ClinicalTrials.gov registry record
Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer
A clinical trial of Acute Leukemia, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 332
- Enrollment target
- 8
- Study locations
NCT05035615 is a study of Acute Leukemia that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 332 participants, below the 454-participant average among 37 other Acute Leukemia trials with a reported enrollment target (27% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT05035615, a study of Acute Leukemia, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 332 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST IUO Acute Leukemia Panel
Study Locations (8)
Other
- Fleury Group - São Paulo
- Motol University Hospital, Childhood Leukemia Investigation - Prague
- University of Salamanca - Salamanca
- Cambridge University - Cambridge
California
- Childrens Hospital Los Angeles - Los Angeles
New York
- New York-Presbyterian Hospital Weill Cornell Medicine - New York
North Carolina
- University Of North Carolina - Chapel Hill
Texas
- CorePath Laboratories - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2024-07-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05035615
The ClinicalTrials.gov registry entry for NCT05035615 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 37 other Acute Leukemia trials with a reported enrollment target (27% lower). The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Leukemia appearing as the primary indexed condition, and to 1 intervention - of which IUO Acute Leukemia Panel is the first listed.
NCT05035615 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT05035615 about?
NCT05035615 is a clinical study titled "Evaluation of the BD OneFlow Acute Leukemia Panel on the BD FACSLyric Flow Cytometer". This study is a multi-site, prospective performance study to determine equivalency between the investigational OneFlow Acute Leukemia Panel on the FACSLyric system versus the final clinical diagnosis.
What is the current status of trial NCT05035615?
This trial is currently completed. The enrollment target is 332 participants. The study started on 2021-11-02. Estimated completion is 2024-07-18.
What conditions does trial NCT05035615 study?
This clinical trial studies the following conditions: Acute Leukemia.
What interventions are being tested in trial NCT05035615?
The interventions under investigation include: IUO Acute Leukemia Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05035615?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05035615 being conducted?
This trial has 8 study locations across California, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.